Goldman Sachs’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.41M | Buy |
|
|||||
|
2025
Q1 | $1.07M | Sell |
|
|||||
|
2024
Q4 | $2.81M | Buy |
|
|||||
|
2024
Q3 | $746K | Buy |
|
|||||
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $606K | Sell |
|
|||||
|
2023
Q4 | $742K | Sell |
|
|||||
|
2023
Q3 | $632K | Buy |
|
|||||
|
2023
Q2 | $663K | Buy |
|
|||||
|
2023
Q1 | $651K | Buy |
|
|||||
|
2022
Q4 | $609K | Sell |
|
|||||
|
2022
Q3 | $2.86M | Buy |
|
|||||
|
2022
Q2 | $2.19M | Buy |
|
|||||
|
2022
Q1 | $1.87M | Sell |
|
|||||
|
2021
Q4 | $4.73M | Sell |
|
|||||
|
2021
Q3 | $8.54M | Buy |
|
|||||
|
2021
Q2 | $8.61M | Buy |
|
|||||
|
2021
Q1 | $5.5M | Sell |
|
|||||
|
2020
Q4 | $10.2M | Buy |
|
|||||
|
2020
Q3 | $2.24M | Buy |
|
|||||
|
2020
Q2 | $598K | Sell |
|
|||||
|
2020
Q1 | $3.47M | Sell |
|
|||||
|
2019
Q4 | $6.66M | Buy |
|
|||||
|
2019
Q3 | $5.42M | Buy |
|
|||||
|
2019
Q2 | $5.61M | Sell |
|
|||||
|
2019
Q1 | $5.63M | Sell |
|
|||||
|
2018
Q4 | $9.48M | Buy |
|
|||||
|
2018
Q3 | $6.76M | Buy |
|
|||||
|
2018
Q2 | $5.61M | Buy |
|
|||||
|
2018
Q1 | $1.81M | Buy |
|
|||||
|
2017
Q4 | $1.82M | Buy |
|
|||||
|
2017
Q3 | $477K | Buy |
|
|||||
|
2017
Q2 | $504K | Sell |
|
|||||
|
2017
Q1 | $632K | Sell |
|
|||||
|
2016
Q4 | $1.47M | Sell |
|
|||||
|
2016
Q3 | $6.49M | Buy |
|
|||||
|
2016
Q2 | $246K | Buy |
|
|||||
|
2016
Q1 | $170K | Buy |
|
|||||
|
2015
Q4 | $180K | Buy |
|
|||||
|
2015
Q3 | $104K | Sell |
|
|||||
|
2015
Q2 | $263K | Sell |
|
|||||
|
2015
Q1 | $435K | Sell |
|
|||||
|
2014
Q4 | $532K | Buy |
|
|||||
|
2014
Q3 | $187K | Sell |
|
|||||
|
2014
Q2 | $600K | Sell |
|
|||||
|
2014
Q1 | $857K | Buy |
|
|||||
|
2013
Q4 | $527K | Sell |
|
|||||
|
2013
Q3 | $1.23M | Buy |
|
|||||
|
2013
Q2 | $312K | Buy |
|